Septal myectomy can alter the underlying cardiac substrate in HCM patients, potentially causing delayed T-wave oversensing and inappropriate SICD shocks.
Answers are grounded in this paper and cite their sources.
May warrant post-myectomy S-ICD re-screening in HCM; leaves open need for prospective validation.
Subcutaneous implantable cardioverter-defibrillators (SICD) are effective for primary prevention in patients with hypertrophic cardiomyopathy (HCM), and proper screening can prevent oversensing despite significant left ventricular hypertrophy. Invasive treatment for HCM, however, may change the underlying substrate and impact appropriate SICD screening.
No takes yet. Share an insight, caveat, or question.
Salgado et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: